Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02266394 · ClinicalTrials.gov registry record · Phase 1
Hypoxia and Inflammatory Injury in Human Renovascular Hypertension
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT02266394: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT02266394 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 42 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02266394, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
Current treatments for ARAS based on restoring blood flow alone have been unsuccessful at recovering kidney function. For this reason we are studying a stem cell product called "mesenchymal stem cells" or MSC. Mesenchymal stem cells (MSC) are grown from a person's own fat tissue (obtained as a fat biopsy) and infused back into the patient's own kidney. This study is also being done to determine if the MSC infusion prior to percutaneous transluminal renal angioplasty with stenting (PTRA) further enhances changes in single kidney blood flow and restoration of kidney function, as well as to assess the relationship between MSC dose and measures of kidney function.
Interventions
- DRUG Mesenchymal stem cell
- PROCEDURE Mesenchymal stem cell delivery with stent placement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2014-10-21 |
| Est. Completion | 2020-09-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02266394
The ClinicalTrials.gov registry entry for NCT02266394 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Mesenchymal stem cell is the first listed.
NCT02266394 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02266394 about?
NCT02266394 is a clinical study titled "Hypoxia and Inflammatory Injury in Human Renovascular Hypertension". Current treatments for ARAS based on restoring blood flow alone have been unsuccessful at recovering kidney function. For this reason we are studying a stem cell product called "mesenchymal stem cells" or MSC. Mesenchymal stem cells (MSC) are grown from a person's own fat tissue (obtained as a fat b...
What is the current status of trial NCT02266394?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2014-10-21. Estimated completion is 2020-09-25.
What interventions are being tested in trial NCT02266394?
The interventions under investigation include: Mesenchymal stem cell (DRUG), Mesenchymal stem cell delivery with stent placement (PROCEDURE).
Who is sponsoring clinical trial NCT02266394?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.